Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VentriPoint Diagnostics Ltd. (VPTDF) Pursues European and Canadian Approvals for New Non-Specific Heart Disease Application
Today before the opening bell, VentriPoint Diagnostics announced it has filed for CE Mark and Health Canada approvals for its database for non-specific heart disease (NRV). By using this database, clinicians can rapidly and accurately assess the status of the right ventricle (RV) in all patients that do not have significant congenital heart defects or Pulmonary Arterial Hypertension (PAH), yet may have a variety of other conditions, such as left-heart failure or valve disease.
“Our customers have asked for the NRV application so they can assess the RV in virtually every patient they see,” said Dr. George Adams, CEO of VentriPoint. “RV assessments are important in all heart patients and we are proud to offer this cost-effective extension to our VMS™ products.”
Approximately 27 million people in the world population have some form of heart disease. VentriPoint Diagnostics’ NRV database will provide a direct avenue for clinicians to better evaluate and care for these individuals. VentriPoint Diagnostics anticipates receiving a response from the European CE Mark and Health Canada offices in the next 30 days.
The database will be used alongside the VMS-2DE™ heart analysis system for patients where knowledge of the function of the right heart could be used to assess the overall heart function to optimally treat the patient. It can also be used to provide a reference baseline study for patients who are at risk for developing right heart dysfunction and would benefit from regular monitoring. Medical research has shown an accurate understanding of the right heart function greatly informs the physician of both right and left heart failure, but it has been hard to obtain this information in a rapid and cost-effective manner until now.
The VMS-2DE™ is approved for clinical use in Tetralogy of Fallot, dextro-Transposition of the Great Arteries (d-TGA) and PAH in Canada and Europe and is for investigational use only in the United States.
For more information, visit www.ventripoint.com
Upcoming Events
VentriPoint will be at the following events with a booth setup to talk to people about the company and its product:
AEPC - Association for European Paediatric and Congenital Cardiology - London, UK
May 22-25, 2013
ASE - American society of echocardiography - Minneapolis, MN, USA
June 29-July 2, 2013
EuroECHO - Istanbul, Turkey
December 11-14, 2013
Recent EventsAEPC - Association for European Paediatric and Congenital Cardiology - Istanbul, Turkey
May 23-26, 2012
PHA - Pulmonary Hypertension association - Orlando, FL, USA
June 22-24, 2012
ASE - American society of echocardiography - Gaylord National, National Harbor, MD, USA
June 30-July 3, 2012
ESC - European Society of Cardiology - Munich, Germany (Hall B2 B101)
Aug 25-29, 2012
ERS - European Respiratory Society - Vienna, Austria (Hall E1.06)
Sept 1-5, 2012
European Echocardiography Course - Barcelona, Spain
October 2-6, 2012
Right Heart Failure Summit 2012 - Boston, MA, USA
October 12-13, 2012
EuroECHO - Athens, Greece
December 5-8, 2012
The Management Team
George Adams, CEO - B.A.Sc., M.A.Sc., Ph.D., ICD.D
• Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010.
• He continues as Chairman of Sernova Corp (TSXV:SVA). He was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009.
• Dr. Adams was the President and CEO of the UT Innovations Foundation from 1999 until 2004.
• Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service.
• He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies.
• Dr. Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.
Florence H. Sheehan, M.D. - Founder, Chief Scientist
• Professor of Medicine/Cardiology at the University of Washington.
• Twenty-seven years experience in cardiac image analysis.
• Developed the centerline method for measuring regional ventricular function.
• Directed the development of the CenterLine wall motion method. This method carries an FDA 510(k) and has been licensed to 15 companies, bringing in $1,466,326 to date.
• Holds 7 patents in the field of quantitative cardiac imaging.
• Director of the Cardiovascular Research and Training Center at the UW, which has served as the Core Laboratory for image analysis to over a dozen multi-center clinical trials.
Christine Deaton - Vice President, CFO
• Twenty years of professional finance experience with an emphasis on gross profit improvement, cost restructuring and process re-engineering.
• Finance Director for LexBlog – initiated budget and cash flow models to align initiatives and product roadmap. Participated in financings and Board discussions.
• Manager of Accounting at SourceCode Technology Holdings – responsible for Business Models, International Consolidations, & KPI Dashboards leading to strong placement in Technical Workflow sector. Key in providing timely management reports for cash management. Created models and tools for revenue recognition and IFRS conversion.
• Expertise in ERP & CRM tools, including Integrations & Implementations for emerging International technology companies.
Amol Karnick - Vice President, Sales and Business Development
• More than eighteen years of medical imaging experience.
• Seven years experience at GE Healthcare in various roles, including mergers and acquisitions where he helped drive $150 million in imaging sales as well as integrating 4 companies.
• Chief Operating Officer for Sentinelle Medical Incorporated - where he was responsible for Engineering, Service, Manufacturing and Regulatory affairs.
• General Manager at Ultrasonix Medical Corporation, where he created and led the service team and directly grew sales through business development.
• Global expertise and experience working with multiple cultures around the world.
• Masters in Electrical Engineering (ultrasound) from McGill University.
Scott Ashley - Vice President, Research and Development
• Twenty-six years of core operating system software development, project management, first-line, second-line, and director experience.
• Director of software development for HP Integrity NonStop NS16000 Server. Managed a team of over 80 software developers; operating systems, low-level millicode, compilers, debuggers, QA groups. Either directly controlled or influenced an annual division-wide budget of more than $10M.
• Key driving force across the Tandem NonStop Division introducing quality improvement activities that reduced defect introduction rates and increased schedule accuracy.
• Second line management responsibility for Tandem NonStop device driver development group, managing a team of 35 software developers; device driver, device diagnostics, device software quality assurance groups. Responsible for the device driver level changes across those groups for the support of the Tandem NonStop S7000 and S70000 products.
• Manager Tandem device driver group. Responsible for rebuilding a software development group from 1 person to 8 people. Managed all software development activities supporting disk, tape, optical disk and generic SCSI devices. Drove major quality improvement project to re- write the key Tandem NonStop device driver software.
Eyal Schwartz - Chief Architect
• Sixteen years experience leading various Software Development projects.
• Experienced software development leader at Microsoft Corporation in the Windows, MSN, and Entertainment divisions.
• Lead design and development of wide array of technologies including secure distributed systems, advanced user interfaces, client/server and web technologies.
• Owner of ten U.S. patents.
• M.S. in Computer Science from Georgia Institute of Technology
23-page PowerPoint (March 2013)
http://content.stockpr.com/ventripoint/media/692532d8e9567658ab18f77144caa0e6.pdf
Will be fully revamped shortly.
VentriPoint Diagnostics Ltd. (VPTDF) is "One to Watch"
VentriPoint Diagnostics Ltd. leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.
The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis.
VentriPoint Receives US-FDA Acceptance of 510 (K) Submission for
Pulmonary Arterial Hypertension
- US-FDA Begins Substantive Review of PAH
Submission -
SEATTLE, WASHINGTON, Mar 01, 2013 (MARKETWIRE via COMTEX) -- VentriPoint
Diagnostics (TSX VENTURE: VPT) (OTCQX: VPTDF) has received yesterday notice from
the U.S. Food and Drug Administration (US-FDA) that an administrative acceptance
review was conducted on the 510(k) submission for premarket notification for
right heart analysis in Pulmonary Arterial Hypertension (PAH), and it was found
to contain all of the necessary information needed to proceed with the
substantive review.
PAH is the most serious form of the five recognized groups of pulmonary
hypertension and is a devastating disease with an average patient lifespan of
less than 3 years after diagnosis if untreated. It affects individuals from
infancy to the elderly. Although treatment started early after detection appears
more effective than when started later, the majority of patients with PAH
continue to be diagnosed too late for treatment to be fully effective.
PAH can occur for no known reason but will typically occur in association with
many common conditions such as chronic liver disease and liver cirrhosis;
connective tissue disorders such as scleroderma or systemic lupus erythematosus
(lupus); congenital heart disease (even if repaired) and HIV. With increasing
availability of effective therapies, and evidence-based treatment guidelines
recommending starting treatment early, tests enabling detection as early as
possible should prove invaluable.
The VMS(TM) is for investigational use only in the United States and approved
for clinical use in Canada and Europe.
About VentriPoint Diagnostics Ltd.
VentriPoint has created diagnostic tools to monitor patients with heart disease,
a leading cause of death in developed countries. VMS(TM) is the first
cost-effective and accurate diagnostic tool for measuring right ventricle heart
function. The Company has a suite of applications for all major heart diseases
and imaging modalities including congenital heart disease, left or right heart
failure and normal hearts - a multi-billion dollar market potential. Canada and
Europe (CE Mark) have granted approval for the sale of its VMS-2DE(TM) product.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release
I'm still hunting for why the price dropped so dramatically today 02/27/13, it triggered a buy I had at .08
Abbs
Co-Exhibited With Toshiba Medical Systems
I am absolutely amazed that considering the other diagnostic applications of their technology that are in the pipeline beyond its use for Right-Heart Analysis for Pulmonary Arterial Hypertension, that this company has basically flown under investors radar. I expect that is about to change shortly.
Interest building
Now that FDA submission is a done deal , VPT should get some deserved attention. The potential for this company's technology is great and SP at these levels is a gift to the investors. It was interesting to see the recent price manipulations ...
Things To Consider
The 400 potential customers mentioned in the prior new release. The expanded potential customers once FDA gives the green light. How does Toshiba fit into the future?
When does Ventripoint expect to hear back from FDA on latest clinical trial of its product?
Abbs
Yellow sticky?????
Ventripoint still very much relevant
http://www.4-traders.com/news/VentriPoint-Diagnostics-Ltd-Results-from-VentriPoint-Pilot-Study-in-Pulmonary-Arterial-Hypertensi--14488173/
http://www.healthcareglobal.com/press_releases/medical-devices/ventripoint-to-present-at-the-2012-aegis-healthcare-conference
meassage from Dr. George Adams, CEO It is exciting times here at VentriPoint as we have successfully developed a novel way to reconstruct a 3-D image of the heart by identifying anatomical sites in the heart (the dots) and then using an expert database to connect all the dots to form a precise image of the shape and size of the heart. One condition where doctors are particularly challenged is blue-baby syndrome (Tetralogy of Fallot), a congenital heart defect that affects newborn babies. It is very difficult, often impossible, to get accurate measurements of these tiny hearts in order to determine the best way and time to operate on the child to surgically repair the defect.
We are gearing up to enable leading pediatric care centers around the world to conduct clinical trials using the VMS™ to demonstrate its universal application to diagnose and monitor many types of heart disease. We already have regulatory approval to sell the system in Europe and Canada. We recently have submitted a response to the US FDA with additional clinical case studies and the agency is evaluating our submission.
reconstruction video of the heart on Ventripoint website http://ventripoint.com/investor/movie.html
thanks Mike! from a glance at the chart it looks like it wants to climb a little...i want to call and speak with the man in charge...see what i can find out!
president and ceo of VentriPoint Diagnostics Ltd. appeared on "the next biggest winner"
http://www.thenextbiggestwinner.com/ventripoint-diagnostics-ltd/
president and ceo of VentriPoint Diagnostics Ltd. appeared on "the next biggest winner"
http://www.thenextbiggestwinner.com/ventripoint-diagnostics-ltd/
this company better pick up some big news to get intrest going no Big blocks or SEC filings nothing...a risk but I am hoping they are starting something new and big..I will try and call monday and see what I can gather more on thier project.
WOW! this stock has never reached higher than .26 it'sgonna need some serious success and approval...i think i will take a chance on it..but has it already went through the 3 phases? gotta check that out!!
VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT)(OTCQX:VPTDF) is pleased to announce that Mayo Clinic has joined its multi-centre clinical trial to evaluate the use of an ultrasound diagnostic tool (the VMS(TM) heart analysis system) for patients with pulmonary arterial hypertension (PAH). Robert Frantz, M.D., a consultant in the Cardiovascular Division and Associate Professor of Medicine, College of Medicine, Mayo Clinic is the lead investigator for the clinical trial site in Rochester, MN.
The VMS(TM) is for investigational use only in the United States and is approved for sale and clinical use in Canada and Europe. VentriPoint is pursuing US-FDA approval through the 510(k) process.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Contacts:
VentriPoint Diagnostics Ltd.
Dr. George Adams, CEO
(206) 283-0221, ext. 401
gadams@ventripoint.com
www.ventripoint.com
Howard Group Inc.
David Burwell, Investor Relations
1.888-221-0915 or 403-221-0915
dave@howardgroupinc.com
VentriPoint 3D Heart Analysis System Approved for Pulmonary Arterial Hypertension in Canada`5
http://tmx.quotemedia.com/article.php?newsid=50995629&qm_symbol=VPT
VentriPoint Launches Clinical Trial in Pulmonary Arterial Hypertension (PAH) in the United States and Canada
http://tmx.quotemedia.com/article.php?newsid=50904513&qm_symbol=VPT
VentriPoint Announces Proposed Private Placement
SEATTLE, WASHINGTON--(Marketwire - April 19, 2012) -
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT) (PINKSHEETS:VPTDF.PK) announces that it intends to complete a non-brokered private placement of up to 12,500,000 units ("Units") of the Corporation at a price of
.16 per Unit for gross proceeds of up to $2,000,000 (the "Private Placement"). Each Unit will consist of one common share ("Common Share") of the Corporation and one-half of one Common Share purchase warrant ("Warrant"), with each Warrant entitling the holder thereof to purchase one Common Share at a price of
.25 per share for a period of two years from the date of issuance. The Corporation intends to use the proceeds from the Private Placement for general working capital purposes.
The Private Placement is subject to the approval of the TSX Venture Exchange. The Common Shares will be subject to a four-month hold period, in accordance with applicable securities laws.
The Corporation may pay a commission or finder's fee to eligible parties in connection with the Private Placement, subject to compliance with applicable securities laws. In addition, the Corporation may grant agent's options to purchase Common Shares at a price of
.16 per Common Share for a period of 18 months, subject to regulatory approval.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
The offered securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold in the United States or to "U.S. persons," as such term is defined under Regulation S promulgated under the U.S. Securities Act, absent registration under such laws or pursuant to an exemption from registration therefrom.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
CE is the equivalant of UL listing in U.S.
This is similar to FDA 510K review in Europe
Does my product need CE Marking?
CE Marking is most probably required if you export to the 27 European Union (EU) and 3 European Free Trade Association (EFTA) member states the following 20 groups of products -
More info
http://en.wikipedia.org/wiki/CE_mark
What is "CE" approval?......LOL
VentriPoint 3D Heart Analysis System First to Be Approved for Pulmonary Hypertension in Europe
VentriPoint to market PAH application in Europe
SEATTLE, WASHINGTON--(Marketwire - March 29, 2012) - VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) is pleased to announce that it has received CE Approval for the Company's new Pulmonary Arterial Hypertension (PAH) application for the VentriPoint Medical System™ (VMS™). Easier than Magnetic Resonance Imaging (MRI) and safer than catheterization, without sacrificing accuracy, this application enables repeated monitoring of the right ventricle that ensures patients receive appropriate treatment. Sales and marketing of the PAH application in Europe will commence immediately.
Dr. Robyn Barst, Professor Emeritus of Pediatrics in Medicine at Columbia University College of Physicians & Surgeons and a member of the VentriPoint Scientific Advisory Board states, "Assessment of right ventricular (RV) function is essential for the management of patients with Pulmonary Arterial Hypertension." Furthermore, "To date, cardiac catheterization and cardiac MRI are the "gold standard" for invasive and non-invasive assessment of the RV in PAH. The novel non-invasive VMS technique provides accurate measurement of RV volumes and RV function in PAH (not feasible utilizing the currently available 2D and 3D echocardiographic imaging). This novel technique should prove useful in assessing efficacy with therapeutic interventions in patients with PAH."
VentriPoint's VMS heart analysis system is fast, accurate and non-invasive. The VMS technique benefits patients who cannot lie flat for up to an hour to undergo an MRI; patients with severe PAH must lie at an angle or sit up to avoid fluid buildup in their lungs. Furthermore, when using the VentriPoint system there is no need for catheterization, an invasive and frequently risky procedure.
"Securing approval to market our PAH application in Europe is an important milestone for the Company. I am very pleased that we can respond to growing demand among prospective customers in the European markets," said Dr. George Adams, President and CEO of VentriPoint.
About Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension, the most serious form of the five recognized groups of pulmonary hypertension, is a devastating disease with an average patient lifespan of less than 3 years after diagnosis if untreated. It affects individuals from infancy to the elderly. Although treatment started early after detection appears more effective than when started later, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. PAH can occur for no known reason but will typically occur in association with many common conditions such as chronic liver disease and liver cirrhosis; connective tissue disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. With increasing availability of effective therapies, and evidence-based treatment guidelines recommending starting treatment early, tests enabling detection as early as possible should prove invaluable.
VentriPoint 3D Heart Analysis System has received CE Approval
http://tmx.quotemedia.com/article.php?newsid=49830228&qm_symbol=VPT
VentriPoint Diagnostics Ltd. Joins OTCQX
NEW YORK, March 28, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for OTC-traded equities, announced that VentriPoint Diagnostics Ltd. (OTCQX: VPTDF; TSX.V: VPT), a Canada-based medical device company, is now trading on the highest tier of the OTC market, OTCQX®.
(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO )
VentriPoint Diagnostics began trading today on the OTC market's prestigious tier, OTCQX International. Investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
"The OTCQX platform supports a transparent marketplace with high quality issuers, financial information disclosure and efficient trading for U.S. investors," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome VentriPoint Diagnostics to OTCQX."
Berns & Berns, Counsellors at Law will serve as VentriPoint Diagnostics' Principal American Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements and U.S. securities laws.
About VentriPoint Diagnostics Ltd.
VentriPoint Diagnostics Ltd. (OTCQX: VPTDF; TSX.V: VPT) trades in the United States on OTCQX under the symbol "VPTDF", in Canada on the TSX Venture under the symbol "VPT". VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest OTC marketplace for equity securities. Our OTC Link® trading system delivers price transparency in over 10,000 securities and enables direct interaction between broker-dealers that provide liquidity and execution services. We organize the marketplace by categorizing the wide spectrum of OTC-traded companies into three tiers: OTCQX - The Intelligent Marketplace for the Best OTC Companies; OTCQB® - The Venture Marketplace; and OTC Pink® - The Open Marketplace. Our information-driven platform makes it easy for investors to trade at the best price through the broker of their choice and empowers companies to build the best markets for their investors. To learn more about our Open, Transparent, and Connected marketplace, visit www.otcmarkets.com.
Subscribe to the OTCQX RSS Feed
SOURCE OTC Markets Group Inc.
Hey MACDgyver thats a lot of links for sure!
Could you do one on TDCP and TCLN?
Thease are ones that I think have great potential.
Thanks
<<< $VPTDF Links! >>> ~ MAC's Quick DD Links without the charts.
PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/VPTDF
OTC Markets Company Info ~ http://www.otcmarkets.com/stock/VPTDF/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/VPTDF/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/VPTDF/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/VPTDF/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/VPTDF/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/VPTDF/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/VPTDF/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/VPTDF/research
Google Finance Summary ~ http://www.google.com/finance?q=VPTDF
Google Finance News ~ http://www.google.com/finance/company_news?q=VPTDF
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=VPTDF
Google Finance Financials ~ http://www.google.com/finance?q=VPTDF&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=VPTDF
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=VPTDF&histperiod=weekly#
Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=VPTDF+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=VPTDF+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=VPTDF+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=VPTDF
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=VPTDF+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=VPTDF+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/VPTDF
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/VPTDF
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=VPTDF+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=VPTDF+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=VPTDF+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=VPTDF+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=VPTDF+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=VPTDF+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=VPTDF+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=VPTDF+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=VPTDF+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=VPTDF+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=VPTDF+Cash+Flow&annual
FINVIZ ~ http://finviz.com/quote.ashx?t=VPTDF&ty=c&ta=0&p=d
Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=VPTDF
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=VPTDF
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=VPTDF
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=VPTDF
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=VPTDF
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=VPTDF&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260
CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=VPTDF&exchange=US
Barchart Quote ~ http://barchart.com/quotes/stocks/VPTDF?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/VPTDF
Barchart Options Quotes ~ http://barchart.com/options/stocks/VPTDF
Barchart Technical Chart ~ http://barchart.com/charts/stocks/VPTDF&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/VPTDF&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/VPTDF
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=VPTDF
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/VPTDF
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/VPTDF
Barchart News Headlines ~ http://barchart.com/news/stocks/VPTDF
Barchart Profile ~ http://barchart.com/profile//VPTDF
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=VPTDF&view=key_statistics
OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=VPTDF&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=VPTDF&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=VPTDF&MarketTicker=NYSE&Typ=S
Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/VPTDF/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/VPTDF/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/VPTDF/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/VPTDF/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/VPTDF
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/VPTDF/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/VPTDF/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/VPTDF/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/VPTDF/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/VPTDF/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/VPTDF/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=VPTDF&sid=1795093&framed=False
The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=VPTDF
Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=VPTDF
StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=VPTDF&num1=567&cobrand=&mode=stock
StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=VPTDF
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=VPTDF
AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=VPTDF&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8
Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=VPTDF.PK&WTmodLOC=C4-Officers-5
StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=VPTDF®ion=U
Search NASDAQ ~ http://www.nasdaq.com/symbol/VPTDF
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/VPTDF/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/VPTDF/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/VPTDF/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=VPTDF&selected=VPTDF
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=VPTDF&selected=VPTDF
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/VPTDF/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/VPTDF/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/VPTDF/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/VPTDF/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/VPTDF/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/VPTDF/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/VPTDF/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/VPTDF/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/VPTDF/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/VPTDF/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/VPTDF/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/VPTDF/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/VPTDF/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/VPTDF/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=VPTDF&selected=VPTDF
NASDAQ Financials ~ http://www.nasdaq.com/symbol/VPTDF/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/VPTDF/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/VPTDF/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/VPTDF/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/VPTDF/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/VPTDF/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/VPTDF/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/VPTDF/insider-trades/sells
The Motley Fool ~ http://caps.fool.com/Ticker/VPTDF.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/VPTDF/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/VPTDF/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/VPTDF/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/VPTDF/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/VPTDF/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/VPTDF/Statements.aspx?source=icasittab0000009
MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=VPTDF
YCharts ~ http://ycharts.com/companies/VPTDF
YCharts Performance ~ http://ycharts.com/companies/VPTDF/performance
YCharts Dashboard ~ http://ycharts.com/companies/VPTDF/dashboard
InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=VPTDF&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=VPTDF&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=VPTDF&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=VPTDF
Zacks Quote ~ http://www.zacks.com/stock/quote/VPTDF
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=VPTDF
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=VPTDF
Knobias ~ http://knobias.10kwizard.com/files.php?sym=VPTDF
StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=VPTDF
Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/VPTDF/HOT_TOPIC.html
Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=VPTDF&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=VPTDF®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=VPTDF®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=VPTDF®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=VPTDF®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=VPTDF®ion=USA&culture=en-us
CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=VPTDF
TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=VPTDF
OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=VPTDF&searcharea=e&image1.x=0&image1.y=0
Insidercow ~ http://www.insidercow.com/history/company.jsp?company=VPTDF&B1=Search%21
Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=VPTDF
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=VPTDF&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null
YouTube Symbol Search ~ http://www.youtube.com/results?search_query=VPTDF
Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=VPTDF
Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=VPTDF
Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=VPTDF
Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=VPTDF
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=VPTDF
Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=VPTDF
Investorpoint ~ http://www.investorpoint.com/ enter "VPTDF" and click search.
Hotstocked ~ http://www.hotstocked.com/ enter "VPTDF" and click search.
Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=VPTDF
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=VPTDF
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=VPTDF
Check those searches for recent VPTDF mentions. If VPTDF is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
MACDlinks
Ready to move..
Looks like we're ready to move higher. Volumes good and charts positive (particularly in Canadian exchange http://tmx.quotemedia.com/quote.php?qm_symbol=VPT).
Company seems to be putting all the pieces together nicely. Once FDA approval is shown, and latest European and Canadian approvals are acheived, we'll get a real nice boost. This stock is a no brainer at this price point. Product already being used and sales will surely increase as time moves forward.
Going to spread the word. B'marked.
VentriPoint Completes Validation Study for Pulmonary Arterial Hypertension Application
http://tmx.quotemedia.com/article.php?newsid=48805208&qm_symbol=VPT
VentriPoint Installs First Updated VMS(TM) Heart Analysis System
Read more: http://www.digitaljournal.com/pr/581129#ixzz1lzkyh0Df
http://www.digitaljournal.com/pr/581129
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
94
|
Created
|
02/09/12
|
Type
|
Free
|
Moderators |
VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
The company's VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.
The management team executing VentriPoint's business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company's technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis.
Ventripoint Diagnostics Ltd.
100 W. Harrison St.
North Tower Unit 410
Seattle, WA 98119, United States
Phone: (206) 283-0221
Email: info@ventripoint.com
Fit verified by operator viewing borders on 2D views
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |